Articles related to CONTRACEPTION/BIRTH CONTROL

Experts highlighted ongoing barriers and knowledge gaps affecting reproductive care for transgender and gender-diverse patients while outlining strategies to support pregnancy, postpartum care, and fertility discussions in affirming clinical environments.

The FDA approved a low-estrogen weekly contraceptive patch for pregnancy prevention in eligible women with BMI below 30 kg/m². Approval was supported by Phase 3 efficacy, safety, and adhesion data, but use remains subject to established combined hormonal contraceptive contraindications.

A clinical review outlines how OBGYNs can integrate GLP-1 receptor agonist therapy into obesity care for women of reproductive age, with attention to fertility, contraception, and adherence.

Paracervical block consistently reduces pain during IUD insertion in vaginally nulliparous patients, while NSAIDs, misoprostol, and nitrous oxide show no clinical benefit across randomized trials.

Foundayo will be available via LillyDirect beginning April 6, with widespread availability through retail pharmacies and telehealth providers occurring soon after.

“The updated label for Nexplanon reflects the diversity of patients we see every day, women throughout their reproductive ages, those seeking a long-acting option of up to 5 years, those who prefer birth control that goes in the arm rather than the uterus, and women across a wide range of BMIs,” said Anita Nelson, MD, Professor, Obstetrics and Gynecology at Western University of Health Sciences.